ZLNAEarnings•globenewswire•
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
Sentiment:Negative (10)
Summary
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 20, 2025 by globenewswire